加载中
NASDAQHealthcareBiotechnology
最新数据
US$2.385
−US$0.055 · -2.25%
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
常规交易时段
US$2.385
−US$0.055 · -2.25%
盘中时间采用ET。市场数据可能有所延迟。
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
日内区间
当前US$2.385
52周区间
当前US$2.385
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
32
偏贵
情绪
45
多空交织
风险
51
风险偏高
动量
62
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
日内区间
当前US$2.385
52周区间
当前US$2.385
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 6626.7万 USD | 5196.4万 USD | 3031.2万 USD | 2708万 USD | 2373.5万 USD |
| 销售、一般及管理费用 | 1698.4万 USD | 1861.3万 USD | 1268.8万 USD | 1270万 USD | 1313.2万 USD |
| 营业费用 | 8325.1万 USD | 7057.7万 USD | 4300万 USD | 8842.8万 USD | 3686.7万 USD |
| 折旧和摊销 | 31.3万 USD | 35.9万 USD | 37.4万 USD | 37.3万 USD | 19.5万 USD |
| 营业利润 | −8325.1万 USD | −7057.7万 USD | −4300万 USD | −8842.8万 USD | −3686.7万 USD |
| 净利润 | −4561.7万 USD | −3618.4万 USD | −1.17亿 USD | −8796.6万 USD | −3450.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.00
上涨空间 193.50%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2020年10月5日 | 1:18 | — | — |
股票拆分 | 2017年5月11日 | 1:9 | — | — |
已生效 2020年10月5日
1:18
已生效 2017年5月11日
1:9
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI739.98万0.00%2.3万亿 USD0.03%US$381.26-0.08%
iShares Russell 2000 ETFIWM494.97万0.01%787.4亿 USD0.19%US$276.53-0.49%
Vanguard Extended Market ETFVXF254.68万0.00%954亿 USD0.05%US$232.36-0.50%
iShares Russell 2000 Growth ETFIWO175.83万0.01%139.17亿 USD0.24%US$351.38-0.66%
Vanguard Russell 2000 ETFVTWO131.58万0.01%180亿 USD0.06%US$111.68-0.53%
Dimensional - US Small Cap ETFDFAS62.43万0.00%338.04亿 USD0.31%US$78.005-0.21%
iShares Micro-Cap ETFIWC58.91万0.05%13.17亿 USD0.60%US$180.61-0.58%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC27.75万0.03%10.47亿 USD0.20%US$85.92-0.39%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
